Schizophrenia Clinical Trial
Official title:
Phase 1, Open-Label Positron Emission Tomography (PET) Study to Evaluate D2 Receptor Occupancy Following Single Intravenous Administration of ATI-9242 in Adult Male Healthy Subjects
Verified date | July 2017 |
Source | Braeburn Pharmaceuticals |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study involves evaluating the occupancy of ATI-9242 at steady state at three different dose levels on D2 receptors in the brain using [18F] Fallypride PET in up to three cohorts of subjects.
Status | Completed |
Enrollment | 7 |
Est. completion date | November 8, 2016 |
Est. primary completion date | September 6, 2016 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Male |
Age group | 18 Years to 50 Years |
Eligibility |
Inclusion Criteria: - Are males > 18 years of age and < 50 years of age. - BMI <30 - Are in good health as determined by past medical history, physical examination, vital signs, electrocardiogram, and laboratory tests at screening. - Are able to communicate well with the investigator, to understand and comply with the requirements of the study, and understand and sign the written informed consent. - Provide informed consent for study procedures. - Male subjects and their partners of childbearing potential must commit to the use of two methods of contraception, one of which is a barrier method for male subjects and for 90 days after the end of the study. - Subjects must not donate sperm for the study duration and for 90 days after the end of the study. - Willing and able to cooperate with study procedures - A brain MRI within the past 120 days with no evidence of active or focal neurological disease that may interfere with the [18F]Fallypride PET data. Exclusion Criteria: - Use of any prescription drugs, herbal supplements, within four (4) weeks prior to Baseline imaging, and/or over-the-counter (OTC) medication, dietary supplements (vitamins included) within two (2) weeks prior to Baseline imaging. If needed (i.e. an incidental and limited need), acetaminophen is acceptable, but must be documented as a concomitant medication/significant non-drug therapy. - Exposure to any investigational drug within the 4 weeks prior to screening visit. - Subjects with a history of exposure to any radiation >15 mSv/year (e.g., occupational or radiation therapy) over the past year. - Donation or loss of 400 ml or more of blood within eight (8) weeks prior to initial dosing, or longer if required by local regulation. - Have a history or presence of any significant cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, or neurological disorders which, in the opinion of the investigator, are capable of altering the absorption, metabolism, or elimination of drugs or posing a health risk to participate in the study. - Have clinically significant findings on laboratory evaluations in the opinion of the investigator. - Have clinically significant findings on ECG evaluation. - A positive Hepatitis B surface antigen (HBsAg), Hepatitis C antibody or HIV test result. - History of drug or alcohol abuse within the 12 months prior to screening, or evidence of such abuse as indicated by the laboratory assays conducted during the screening. - History of tobacco product use within 3 months prior to screening, to be verified by urine cotinine screening. - Implants such as implanted cardiac pacemakers or defibrillators, insulin pumps, cochlear implants, metallic ocular foreign body, implanted neural stimulators, CNS aneurysm clips and other medical implants that have not been certified for MRI. - Claustrophobia that would interfere with completion of MRI and/or SPECT procedures. - Inability to lie supine for 90 minutes at a time. |
Country | Name | City | State |
---|---|---|---|
United States | Indiana Clinical Research Center, IU Health University Hospital | Indianapolis | Indiana |
Lead Sponsor | Collaborator |
---|---|
Braeburn Pharmaceuticals |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Safety and tolerability of ATI-9242 following single IV dose in 6 healthy subjects via safety assessments . | incidence of adverse events (AEs), vital signs (blood pressure, pulse and oral temperature), physical examinations 12-lead ECG, CSSRS and clinical laboratory tests (hematology, clinical chemistry and urinalysis). | approximately 5 weeks | |
Primary | Target receptor occupancy after single intravenous(IV) of ATI-9242 in 6 healthy adults using the D2 receptor ligand [18F]Fallypride and PET imaging. | Change from baseline in PET imaging at baseline of ATI-9242 and post-dose | approximately 5 weeks | |
Secondary | Explore the relationship between ATI-9242 dose, plasma concentrations of ATI-9242 and target receptor occupancy in 6 subjects. | The relationship between plasma drug concentration/PK parameters of ATI-9242 and D2 occupancy will be explored. | approximately 5 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05039489 -
A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT05321602 -
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
|
Phase 1 | |
Completed |
NCT05111548 -
Brain Stimulation and Cognitive Training - Efficacy
|
N/A | |
Completed |
NCT04503954 -
Efficacy of Chronic Disease Self-management Program in People With Schizophrenia
|
N/A | |
Completed |
NCT02831231 -
Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium
|
Phase 1 | |
Completed |
NCT05517460 -
The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center
|
N/A | |
Completed |
NCT03652974 -
Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy
|
Phase 4 | |
Recruiting |
NCT04012684 -
rTMS on Mismatch Negativity of Schizophrenia
|
N/A | |
Recruiting |
NCT04481217 -
Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT00212784 -
Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)
|
Phase 3 | |
Completed |
NCT04092686 -
A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
|
Phase 3 | |
Completed |
NCT01914393 -
Pediatric Open-Label Extension Study
|
Phase 3 | |
Recruiting |
NCT03790345 -
Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics
|
Phase 2/Phase 3 | |
Recruiting |
NCT05956327 -
Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training
|
N/A | |
Terminated |
NCT03209778 -
Involuntary Memories Investigation in Schizophrenia
|
N/A | |
Terminated |
NCT03261817 -
A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders
|
N/A | |
Completed |
NCT02905604 -
Magnetic Stimulation of the Brain in Schizophrenia or Depression
|
N/A | |
Recruiting |
NCT05542212 -
Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia
|
N/A | |
Completed |
NCT04411979 -
Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia
|
N/A | |
Terminated |
NCT03220438 -
TMS Enhancement of Visual Plasticity in Schizophrenia
|
N/A |